MLN9708 Regimen Effective with Reduced Neuropathy Risk in Multiple Myeloma

At the American Society of Hematology annual meeting, Dr. Shaji Kumar presented the results of a recent Phase I/II study conducted at the Mayo Clinic. Newly diagnosed multiple myeloma patients were given an oral regimen containing an experimental preteasome inhibitor – MLN9708. With promising results, more evaluation is being done on relapsed and newly diagnosed myeloma.  READ MORE

Source: TheOncologyReport

Send this to a friend